Non-obese rheumatoid arthritis patients with low low-density lipoprotein have higher coronary atherosclerosis burden, greater plaque progression and cardiovascular event risk
In this medfyle
Expert commentary by Elena Myasoedova, MD, PhD
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Acknowledgements
This is a highlights summary of an oral session given at the ACR Convergence 2020 and presented by:
George Karpouzas, MD
Harbor-UCLA Medical Center and the Lundquist Institute
Torrance, CA, USA
The presenting authors of the original session had no part in the creation of this conference highlights summary.
In addition, an expert commentary on the topic has been provided by:
Elena Myasoedova, MD, PhD
Mayo Clinic, Rochester, MN
The content is produced by Infomedica, an approved ACR education partner. The summary text was drafted by Marie Farrow, and reviewed by Alessia Alunno, MD, PhD, an independent external expert, and approved by Atul Deodhar, MD, MRCP, the scientific editor of the program.
This activity is included in the ACR's Education Partner program. Independent reporting and the viewpoints expressed are those of Infomedica and its affiliates and do not represent the ACR.
About the Expert
Elena Myasoedova, MD, PhD
Mayo Clinic, Rochester, MN
Dr. Myasoedova is a rheumatologist at the Division of Rheumatology at Mayo Clinic, Rochester, MN. She has a joint appointment at the Department of Health Sciences Research, Division of Epidemiology. She holds a rank of Associate Professor of Medicine at Mayo Clinic.
Dr. Myasoedova has a keen interest in clinical outcomes research and individualized medicine. She has authored/co-authored 50 full-length original publications in high-impact peer-review journals, mostly focusing on disease outcomes in patients with RA. She is the recipient of a number of award and grants, most notably she serves as a Principal Investigator (PI) on the R01 grant from the NIA/NIH “Role of systemic inflammation in cognitive decline: rheumatoid arthritis as a prototype”, and a PI on the study “Pharmacogenomics-driven Individualized Prediction of Treatment Response to Methotrexate in Patients with Rheumatoid Arthritis: A Machine Learning Approach” funded by Louis V. Gerstner, Jr. Fund at Vanguard Charitable.
References
1. Semb AG, Ikdahl E, Wibetoe G, et al. Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis. Nat Rev Rheumatol 2020;16:361–79.
3. Myasoedova E, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 2011;70:482–7.
3. Maradit-Kremers H, Nicola PJ, Crowson CS, et al. Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum 2004;50:3450–7.
4. Giles JT, Wasko MCM, Chung CP, et al. Arthritis: Associations of Low Circulating Low-Density Lipoprotein Concentration With Subclinical Coronary Atherosclerosis. Arthritis Rheumatol 2019;71(9):1426–36.
